These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 11514908)

  • 21. Preventive Strategies for Respiratory Syncytial Virus Infection in Young Infants.
    Taveras J; Ramilo O; Mejias A
    Neoreviews; 2020 Aug; 21(8):e535-e545. PubMed ID: 32737172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RSV Prevention Within Reach for Older Infants and Toddlers: The Role of Active Immunization.
    Mejias A; Ramilo O
    J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S125-S130. PubMed ID: 38995087
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RSV disease--is there a role for prevention?
    Lenney W
    Respir Med; 2001 Mar; 95(3):170-2. PubMed ID: 11266232
    [No Abstract]   [Full Text] [Related]  

  • 25. Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives.
    Vittucci AC; Zangari P; Ciarlitto C; Di Camillo C; Grandin A; Cotugno N; Marchili MR; Villani A
    Minerva Pediatr; 2018 Dec; 70(6):566-578. PubMed ID: 30334621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
    Régnier SA
    Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventing Pediatric Respiratory Syncytial Virus Infection.
    Domachowske J; Halczyn J; Bonville CA
    Pediatr Ann; 2018 Sep; 47(9):e371-e376. PubMed ID: 30208197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR; Simoes EA; Hemming VG
    Pediatrics; 1995 Apr; 95(4):463-7. PubMed ID: 7700741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B; Müller W
    Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop.
    Roberts JN; Graham BS; Karron RA; Munoz FM; Falsey AR; Anderson LJ; Marshall V; Kim S; Beeler JA
    Vaccine; 2016 Sep; 34(41):4843-4849. PubMed ID: 27566900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
    Mazur NI; Terstappen J; Baral R; Bardají A; Beutels P; Buchholz UJ; Cohen C; Crowe JE; Cutland CL; Eckert L; Feikin D; Fitzpatrick T; Fong Y; Graham BS; Heikkinen T; Higgins D; Hirve S; Klugman KP; Kragten-Tabatabaie L; Lemey P; Libster R; Löwensteyn Y; Mejias A; Munoz FM; Munywoki PK; Mwananyanda L; Nair H; Nunes MC; Ramilo O; Richmond P; Ruckwardt TJ; Sande C; Srikantiah P; Thacker N; Waldstein KA; Weinberger D; Wildenbeest J; Wiseman D; Zar HJ; Zambon M; Bont L
    Lancet Infect Dis; 2023 Jan; 23(1):e2-e21. PubMed ID: 35952703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR; Hoopes JM; Hemming VG
    Adv Ther; 2011 Feb; 28(2):110-25. PubMed ID: 21318605
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in RSV vaccine research and development - A global agenda.
    Higgins D; Trujillo C; Keech C
    Vaccine; 2016 Jun; 34(26):2870-2875. PubMed ID: 27105562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus.
    Kim JY; Chang J
    Yonsei Med J; 2016 Jul; 57(4):809-16. PubMed ID: 27189271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and epidemiologic features of respiratory syncytial virus.
    Hall CB; Simőes EA; Anderson LJ
    Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice.
    Céspedes PF; Rey-Jurado E; Espinoza JA; Rivera CA; Canedo-Marroquín G; Bueno SM; Kalergis AM
    Vaccine; 2017 Feb; 35(5):757-766. PubMed ID: 28065474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Humanized respiratory syncytial virus monoclonal antibody].
    Tsutsumi H
    Nihon Rinsho; 2002 Mar; 60(3):487-91. PubMed ID: 11904963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapies and vaccines against the human respiratory syncytial virus.
    Rivera CA; Gómez RS; Díaz RA; Céspedes PF; Espinoza JA; González PA; Riedel CA; Bueno SM; Kalergis AM
    Expert Opin Investig Drugs; 2015; 24(12):1613-30. PubMed ID: 26457559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.